{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-21-015885","form_type":"8-K","ticker":"KALA","cik":"0001479419","company_name":"KALA BIO, Inc.","filed_at":"2021-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.698211+00:00","generated_at":"2026-06-28T08:18:31.342557+00:00","sec_items":["1.01","1.02","2.01","2.02","3.02","5.02","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Kala acquires Combangio for $5M cash, $16.1M stock; board adds Blumenkranz","bullets":["Upfront payment $5.0M cash + 7,788,667 shares (~$16.1M) representing 11.9% of Kala's outstanding.","Contingent consideration up to $105M in milestones plus tiered mid-to-high single-digit royalties on KPI-012 sales.","Board appoints Mark Blumenkranz, former Combangio board member, as Class II director; receives option for 42,000 shares.","Kala terminates Watertown lease, receives $2M termination consideration; HQ moves to Arlington, MA; outsources lab activities."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-21-015885","json":"https://secwatch.observer/filing/0001558370-21-015885.json","markdown":"https://secwatch.observer/filing/0001558370-21-015885.md","text":"https://secwatch.observer/filing/0001558370-21-015885.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479419/000155837021015885/0001558370-21-015885-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479419/000155837021015885/kala-20211112x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T08:18:31.342557+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"611cf1ca44","claim":"Mark Blumenkranz was appointed as Director at KALA BIO, Inc..","evidence_excerpt":"Upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”), the Board appointed Mark Blumenkranz as a member of the Board, effective upon the Closing of the Acquisition","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479419/000155837021015885/0001558370-21-015885-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}